Top 10 Metaxalone (Skelaxin) Generic Manufacturers in United Kingdom
The market for muscle relaxants in the United Kingdom has witnessed significant growth due to an increase in musculoskeletal disorders and the rising demand for effective pain management solutions. Metaxalone, marketed under the brand name Skelaxin, is a widely used muscle relaxant that competes with other generics in the market. According to recent statistics, the UK pharmaceutical market was valued at approximately £42 billion in 2022, with generics accounting for about 78% of the total prescriptions. As the healthcare sector continues to prioritize cost-effective treatment options, the demand for generics like Metaxalone is expected to grow.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the world’s largest generic pharmaceutical manufacturers and a key player in the UK market. In 2022, Teva’s revenue from generics reached approximately $16.3 billion globally. The company has a significant share in the UK market, providing quality Metaxalone formulations.
2. Mylan N.V.
Now part of Viatris, Mylan holds a substantial market position in the UK generics sector. While specific figures for Metaxalone are proprietary, Mylan’s overall generics revenue was estimated at $11.5 billion in 2022, indicating strong performance in muscle relaxant medications.
3. Sandoz (Novartis AG)
Sandoz, a division of Novartis, is known for its robust portfolio of generic medications. In 2022, Sandoz’s total sales were around $10 billion, with a significant portion attributed to its muscle relaxant offerings, including Metaxalone.
4. Accord Healthcare
Accord Healthcare, a subsidiary of Intas Pharmaceuticals, is focused on providing high-quality generics in the UK. Their production capacity has expanded significantly, contributing to a market share of approximately 4% in the UK generics market.
5. Aurobindo Pharma
Aurobindo Pharma has made strategic investments in expanding its European operations. In 2022, the company reported a 10% increase in its UK revenue, with muscle relaxants like Metaxalone being key contributors to this growth.
6. Hikma Pharmaceuticals
Hikma, which has a strong presence in the UK, reported revenues of approximately $1.6 billion in generics for 2022. The company has successfully marketed Metaxalone as part of its growing portfolio.
7. Amgen Inc.
Although primarily known for biologics, Amgen has entered the generic market. In 2022, the company achieved a generics revenue of approximately $2 billion, with Metaxalone contributing to their expansion strategy.
8. Lupin Pharmaceuticals
Lupin has made significant strides in the UK generics market, reporting a revenue of around $2.4 billion in 2022. The company has focused on expanding its portfolio in muscle relaxants, including Metaxalone.
9. Zydus Cadila
Zydus Cadila has a growing presence in the UK generic sector, with a revenue of approximately $1.5 billion in 2022. Their investments in R&D have allowed them to produce competitive formulations of Metaxalone.
10. Fresenius Kabi AG
Fresenius Kabi specializes in generic medications and has a strong foothold in the UK market. The company reported approximately $1.8 billion in generics revenue in 2022, with Metaxalone being part of their diverse product lineup.
Insights on the Metaxalone Market Trends
The market for Metaxalone generics in the United Kingdom is projected to grow at a CAGR of approximately 6% over the next five years, driven by increasing demand for affordable treatment options amid rising healthcare costs. Moreover, the NHS’s push towards generics is expected to facilitate further adoption of Metaxalone. As healthcare providers increasingly prioritize cost-effective solutions, companies that invest in R&D to enhance product quality and compliance will likely capture a larger market share. The overall UK pharmaceutical sector is expected to reach £50 billion by 2025, highlighting the potential for continued growth in the generics market, particularly for essential medications like Metaxalone.
Related Analysis: View Previous Industry Report
